MedPeerInc Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Yo Iwami

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	19.4yrs
Eigendom CEO	31.2%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	4.4yrs

Recente managementupdates

Recent updates

Market Participants Recognise MedPeer,Inc.'s (TSE:6095) Earnings Pushing Shares 34% Higher

Sep 04

Estimating The Intrinsic Value Of MedPeer,Inc. (TSE:6095)

Aug 02

MedPeerInc's (TSE:6095) Soft Earnings Don't Show The Whole Picture

May 21

CEO

Yo Iwami (50 yo)

19.4yrs

Tenure

Dr. Yo Iwami, M.D, Ph D., serves as the President and Representative Director of MedPeer,Inc since June 2005 and serves as its CEO. Dr. Iwami has been an Outside Director of Sogo Rinsho Holdings Co., Ltd....

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yo Iwami	President	19.4yrs	geen gegevens	31.16% ¥ 3.8b
Naoki Goto	Executive VP & Director	less than a year	geen gegevens	0.0046% ¥ 564.5k
Makoto Haruta	Management Advisor	no data	geen gegevens	geen gegevens
Takashi Hayama	External Auditor	11.9yrs	geen gegevens	0.38% ¥ 46.9m
Hiroyasu Sato	External Auditor	11.9yrs	geen gegevens	geen gegevens
Masatoshi Kawana	Independent Outside Director	4.9yrs	geen gegevens	geen gegevens
Yoshihiko Tembo	Director	3.9yrs	geen gegevens	0.15% ¥ 18.4m
Toshio Hirabayashi	Director	3.9yrs	geen gegevens	0.28% ¥ 34.8m
Mayuko Seto	Independent Outside Director	1.9yrs	geen gegevens	geen gegevens
Masayuki Shimura	Independent Outside Director	1.9yrs	geen gegevens	0.0014% ¥ 169.4k
Shunichi Sueyoshi	Full Time Auditor	6.9yrs	geen gegevens	geen gegevens

4.4yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 6095 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

MedPeerInc Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

MedPeer,Inc., Annual General Meeting, Dec 15, 2022

No independent directors

No independent directors

MedPeer,Inc., Annual General Meeting, Dec 17, 2020

Recent updates

Upcoming dividend of JP¥4.50 per share

Consensus EPS estimates increase by 31%

Market Participants Recognise MedPeer,Inc.'s (TSE:6095) Earnings Pushing Shares 34% Higher

Now 21% overvalued after recent price rise

MedPeer,Inc. to Report Fiscal Year 2024 Results on Nov 13, 2024

Third quarter 2024 earnings released: EPS: JP¥10.59 (vs JP¥1.28 in 3Q 2023)

Investor sentiment deteriorates as stock falls 27%

Estimating The Intrinsic Value Of MedPeer,Inc. (TSE:6095)

MedPeer,Inc. to Report Q3, 2024 Results on Aug 14, 2024

Consensus EPS estimates increase by 11%

Price target decreased by 13% to JP¥725

Consensus EPS estimates fall by 13%

MedPeerInc's (TSE:6095) Soft Earnings Don't Show The Whole Picture

Second quarter 2024 earnings released: JP¥4.15 loss per share (vs JP¥5.02 profit in 2Q 2023)

New minor risk - Market cap size

MedPeer,Inc. to Report Q2, 2024 Results on May 13, 2024

Consensus EPS estimates fall by 19%, revenue upgraded

Investor sentiment improves as stock rises 22%

First quarter 2024 earnings released: EPS: JP¥13.33 (vs JP¥12.40 in 1Q 2023)

New minor risk - Market cap size

Now 21% undervalued after recent price drop

MedPeer,Inc. to Report Q1, 2024 Results on Feb 13, 2024

New minor risk - Market cap size

Now 21% undervalued after recent price drop

Price target decreased by 9.1% to JP¥1,250

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 13%

Now 27% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

New major risk - Share price stability

Now 21% undervalued after recent price drop

MedPeer,Inc. to Report Fiscal Year 2023 Results on Nov 13, 2023

Third quarter 2023 earnings released: EPS: JP¥1.28 (vs JP¥2.59 in 3Q 2022)

MedPeer,Inc. to Report Q3, 2023 Results on Aug 09, 2023

Now 22% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: JP¥5.02 (vs JP¥10.56 in 2Q 2022)

MedPeer,Inc. (TSE:6095) announces an Equity Buyback for 300,000 shares, representing 1.37% for ¥300 million.

Now 24% undervalued after recent price drop

First quarter 2023 earnings released: EPS: JP¥12.40 (vs JP¥17.15 in 1Q 2022)

MedPeer,Inc. (TSE:6095) acquired Business support application series of recruit Medical Career.

Price target decreased to JP¥2,300

MedPeer,Inc. to Report Q1, 2023 Results on Feb 13, 2023

Now 20% undervalued

Now 23% undervalued

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 19%

MedPeer,Inc., Annual General Meeting, Dec 15, 2022

No independent directors

Price target decreased to JP¥2,600

MedPeer,Inc. (TSE:6095) completed the acquisition of Ep-Force Co.,Ltd. from EPS Holdings, Inc. and others.

MedPeer,Inc. to Report Fiscal Year 2022 Results on Nov 14, 2022

Consensus EPS estimates fall by 30%

Consensus EPS estimates fall by 31%

Third quarter 2022 earnings released: EPS: JP¥2.59 (vs JP¥8.03 in 3Q 2021)

MedPeer,Inc. (TSE:6095) entered into an agreement to acquire Ep-Force Co.,Ltd. from EPS Holdings, Inc. and others for ¥5000 million.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target decreased to JP¥3,580

Investor sentiment deteriorated over the past week

MedPeer,Inc. to Report Q3, 2022 Results on Aug 09, 2022

Price target decreased to JP¥4,276

MedPeer,Inc. (TSE:6095) acquired Minkore recently.

Price target decreased to JP¥4,496

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

No independent directors

MedPeer,Inc. to Report Q2, 2022 Results on May 12, 2022

Now 23% undervalued

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week